Duodenal Neuroendocrine Tumor
Conditions
Keywords
lesion size,, tumour, binding
Brief summary
Primary objective To evaluate the therapeutic efficacy (clinical success) of dEBL at 3 months 2b. Secondary objective To evaluate adverse events, technical success and recurrence on follow-up 50 patients over 1-year duration based on our previous study of Prospective data (2023-2024)
Detailed description
We will collect your basic demographics details like age, Sex, date of admission, Endoscopy (is a test to look inside your body) details of Site, size, number of lesion. By EUS (Endoscopic ultrasound (EUS) combines two techniques - endoscopy and ultrasound - to help doctors see, evaluate and diagnose conditions in and near the gastrointestinal (GI) tract) details of layer of Duodenum involved, site/size/number of lesions. We will collect your details of Duodenal endoscopic band ligation procedure to check feasibility, technical success. You are requested to come for follow up for 3 months for endoscopy prodecure.
Interventions
PROCEDUREduodenal ndoscopic bind ligation
We will collect your basic demographics details like age, Sex, date of admission, Endoscopy (is a test to look inside your body) details of Site, size, number of lesion. By EUS (Endoscopic ultrasound (EUS) combines two techniques - endoscopy and ultrasound - to help doctors see, evaluate and diagnose conditions in and near the gastrointestinal (GI) tract) details of layer of Duodenum involved, site/size/number of lesions. We will collect your details of Duodenal endoscopic band ligation procedure to check feasibility, technical success. You are requested to come for follow up for 3 months for endoscopy prodecure.
Sponsors
Asian Institute of Gastroenterology, India
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients age \>18 years * Size of lesion less than 15mm * Site of lesion- duodenum (d1-d4) * No of lesions- ≤6
Exclusion criteria
* Age less than 18 years * Non-duodenal lesion * Local or distant metastasis * Lumen occluding lesions * Uncorrectable coagulopathy * Not willing for consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Therapeutic efficacy (clinical success) of dEBL at 3 months and 1 year | One year | Therapeutic efficacy (clinical success) of dEBL at 3 months and 1 year |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events and recurrence on follow up | One year | Univariate and multivariate analysis will be done to determine which are the factors associated with clinical success and clinical recurrence |
Countries
India
Outcome results
None listed